Core Viewpoint - Duorui Pharmaceutical (301075) has received approval from the National Medical Products Administration for the injection of Cefoperazone Sodium, indicating a significant development in its product portfolio [1] Company Summary - Duorui Pharmaceutical's wholly-owned subsidiary, Hubei Duorui Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Cefoperazone Sodium injection, with specifications of 0.5g/1.0g [1] - The drug registration certificate is valid until June 9, 2030, with certificate numbers 2025S01726/2025S01727 and approval numbers H20254471/H20254472 [1] Industry Summary - Sales data from 2022 to 2024 for Cefoperazone Sodium injection shows revenue figures of 4.139 billion, 4.144 billion, and 3.078 billion respectively, indicating a slight decline in projected sales for 2024 [1]
多瑞医药：注射用头孢唑肟钠获药品注册证书